Clinical Trials in Meldola, Forlì-Cesena
9 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Patients With Non-small-cell Lung Cancer
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 1Phase 2
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Non-Small-Cell Lung Carcinoma
AbbVie252 enrolled55 locationsNCT06772623
Recruiting
Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
AbbVie520 enrolled264 locationsNCT05445778
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled214 locationsNCT07128199
Recruiting
Phase 3
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
MelanomaMetastatic MelanomaUnresectable Melanoma
Iovance Biotherapeutics, Inc.670 enrolled72 locationsNCT05727904
Recruiting
PRostate Cancer Plasma Integrative Multi-modal Evaluation
Metastatic Prostate Cancer
Santa Chiara Hospital800 enrolled4 locationsNCT06981377
Recruiting
Phase 2
Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML
Acute Myeloid Leukemia
Ryvu Therapeutics SA98 enrolled37 locationsNCT06191263
Recruiting
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled4 locationsNCT06767254
Recruiting
Not Applicable
Integrative "Omics" Approaches for Leukemia Target Identification and Matched Therapeutic Intervention
Leukemia, Acute LymphoblasticMyeloid Leukemia, Acute
Azienda Ospedaliero-Universitaria di Parma100 enrolled8 locationsNCT06626893